Skip to main content
. 2014 Feb 14;9:e201402001. doi: 10.5936/csbj.201402001

Table 1.

Overview of FDA approved ADCs.

mAb Drug Drugs/Ab (average) Chemistry Reducable Trigger Status (US) Ref
Gemtuzumab ozogamicin Calicheamicin 4-6 (5*) Lysine yes pH approved (2000) & withdrawn (2010) [148]
Brentuximab vedotin Monomethyl auristatin E (MMAE) 3-5 (4) Cysteine no protease approved (2011) [143]
Trastuzumab emtansine Mertansine (DM1) 0-8 (3.5) Lysine no none approved (2013) [140]
*

For only 50% of the antibodies